Insight

Highlights from SABCS24 by Stephanie Graff

Stephanie Graff/X

Dec 15, 2024, 11:36

Highlights from SABCS24 by Stephanie Graff

The San Antonio Breast Cancer Symposium (SABCS) 2024 took place from December 10-13 in San Antonio, Texas.

Stephanie Graff

The symposium will feature a comprehensive scientific program, including formal lectures by experts, selected slide and poster presentations, and case discussions focused on experimental biology, prevention, diagnosis, and therapy. With an emphasis on clinical, translational, and basic research, SABCS 2024 aims to foster collaboration and knowledge-sharing among academic and private physicians in oncology, as well as patient advocates and other healthcare professionals. The event will be conducted in English, with no simultaneous translation provided, and offers both in-person and virtual participation opportunities.

Stephanie Graff, Director of Breast Oncology at Brown University Health, shared her highlights from the conference:

Neoadjuvant Camelizumab and Chemotherapy for eTNBC

“Neoadjuvant Camelizumab and Chemo for eTNBC (CamRelief) shows camelizumab meets primary endpoint improving PCR.

The survival outcomes are immature, but insignificant—so at this time does not replace Pembro.

For context: Was conducted entirely in Asia, so while important for global health, will have limited opportunity to expand to US/EU at this time.”

Stephanie Graff

Increasing RS≥31 corresponded to increasing benefit of addition of anthracycline

“In TAILORx (LN- HR+) pts w/ RS≥31 addition of anthracycline results in benefit in 5-yr DRFI (5% HR 0.32) vs TC

Benefit most clear in tumor >2 cm.

Increasing RS≥31 corresponded to increasing benefit of addition of anthracycline.”

Highlights from SABCS24 by Stephanie Graff

Micromets after neoadjuvant portend a worse prognosis

“Micromets after neoadjuvant portend a worse prognosis and we need to develop a subtype-specific approach.”

Highlights from SABCS24 by Stephanie Graff

Making a critical point about how/why PATINA had such a high performance control arm

“Making a critical point about how/why PATINA had such a high performance control arm, Sara Hurvitz describes how the recruitment window excluded patients who had a brisk progression, changing the shapes of the curves.”

Highlights from SABCS24 by Stephanie Graff

PATINA—the addition of palbociclib to HP after discontinuation of docetaxel

“PATINA—the addition of palbociclib to HP after discontinuation of docetaxel in 1L mHER2+BC—results in an improvement in median PFS from 29.1 months to 44.3 months, a HR 0.74.”

Highlights from SABCS24 by Stephanie Graff